Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Early Pregnancy Safety Concerns With ACE Inhibitors Could Affect ARBs

Executive Summary

Concerns about exposure to angiotensin-converting enzyme inhibitors during the first trimester of pregnancy could have consequences for other classes of antihypertensives, including angiotensin II receptor blockers

You may also be interested in...



Rx Safety Gets More Attention From CERTs With Addition Of Health IT Center

The Centers for Education and Research on Therapeutics program will be adding a new center focused on health information technology

Rx Safety Gets More Attention From CERTs With Addition Of Health IT Center

The Centers for Education and Research on Therapeutics program will be adding a new center focused on health information technology

Pregnancy Label Due Date Approaching? Risk, Clinical Info Could Be Split

FDA is seeking to move ahead quickly with new regulations for pregnancy labeling following the release of the physician labeling final rule

Latest News
See All
UsernamePublicRestriction

Register

PS047270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel